Pro Medicus A$17.3bn Cap Exceeds A$261.7m Revenue
Pro Medicus trades at a 66x revenue multiple, with Visage software driving its A$17.3 billion market value.
Key points
- Pro Medicus market cap of A$17.3 billion is 66 times its A$261.7 million operating revenue.
- Visage 7 and RIS/PACS software platforms drive revenue from hospitals in Australia, North America, and Europe.
- The high valuation multiple requires sustained growth in recurring software contracts to justify equity value.
Pro Medicus Limited (ASX: PME) closed with a market capitalization of A$17.3 billion on September 22, 2026. This valuation stands at roughly 66 times the company's reported operating revenue of A$261.7 million, a ratio that defines the current investment calculus for the Australian healthcare technology firm.
The company’s equity value is anchored in its Visage 7 and Visage RIS/PACS platforms, which manage radiology workflows for hospitals and imaging centers across Australia, North America, and Europe. As detailed in data reported by AD HOC NEWS, the significant gap between market value and annual revenue requires sustained contract execution and recurring software demand to maintain the current pricing multiple.
Valuation Multiple Reflects Software Demand
The A$261.7 million revenue figure represents the concrete operating base for Pro Medicus' integrated healthcare imaging software business. Comparing this to the A$17.3 billion market capitalization highlights the premium investors assign to the company's growth trajectory and market position. This 66x multiple indicates that the market is pricing in future expansion rather than just current earnings.
Investors must monitor whether operational growth continues to justify this equity value. The reliance on recurring software contracts means that any slowdown in adoption or contract renewal could pressure the valuation. The current multiple leaves little room for execution errors in key regions like North America and Europe.
Visage Platforms Drive Operational Base
Pro Medicus operates as a founder-led group focused on medical imaging software. The Visage 7 and RIS/PACS products are central to its business model, supporting clinical workflows in diagnostic settings. These platforms constitute the primary source of the A$261.7 million in revenue cited in the September 2026 overview.
The company serves a global customer base, with operations spanning Australia, North America, and Europe. This geographic diversification is material to the business case, as it spreads risk across different healthcare markets. The continued demand for these integrated imaging solutions remains the key driver of the company's operational performance.
Market Checkpoint for ASX Listers
Listed on the Australian Securities Exchange under ticker PME, Pro Medicus sits in the healthcare technology sector. With an ISIN of AU000000PME8, the company's A$17.3 billion market cap makes it a significant player in the medical imaging software space. The current valuation serves as a checkpoint for how the market views the sustainability of its software-driven growth model.
